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PeptidesHepatitis C virus (HCV) infection frequently leads to chronic hepatitis, liver cirrhosis, and hepatocellular
carcinoma. There is no effective therapy or vaccine available to HCV-infected patients other than interferon–
ribavarin combination, which is effective in a relatively small percentage of infected patients. Our previous
results have shown that a synthetic peptide (LAP) corresponding to the N-terminal 18 amino acids of the
Lupus autoantigen (La) was a potent inhibitor of HCV IRES-mediated translation. We demonstrate here that
LAP efﬁciently blocks HCV replication of infectious JFH1 virus in cell culture. Our data suggest that LAP forms
complexes with IRES-transacting factors (ITAFs) PTB and PCBP2. LAP-mediated inhibition of HCV IRES-
mediated translation in vitro could be fully rescued by recombinant PCB and PCBP2. Also transient
expression of PTB / PCBP2 combination signiﬁcantly restores HCV replication in LAP-inhibited cultures.
These results suggest that ITAFs could be potential targets to block HCV replication.
© 2009 Elsevier Inc. All rights reserved.Introduction
Hepatitis C virus (HCV) is an enveloped RNA virus belonging to the
ﬂaviridae family. HCV infection frequently leads to chronic hepatitis,
cirrhosis of the liver, and hepatocellular carcinoma (Saito et al., 1990;
Houghton et al., 1991; Choo et al., 1992). There is currently no
effective therapy or vaccine available to HCV-infected patients other
than interferon–ribavarin combination, which is only effective in a
relatively small percentage of infected patients. HCV has been a
difﬁcult virus to study due to the lack of an adequate, simple and low-
cost animal model. Although the RNA transcribed in vitro from a cDNA
clone of HCV has been shown to be infectious when injected directly
into the livers of chimpanzees (Lolykhalov et al., 1997; Yanagi et al.;
1997), HCV virions have been extremely difﬁcult to propagate in
culture. Recently a unique patient isolate called Japanese fulminant
hepatitis 1 (JFH1) was found to replicate and produce infectious HCV
in cell culture (Wakita et al., 2005). This recent advance has allowed
the processes of HCV entry, infectivity and assembly to be investigated
for the ﬁrst time.
While cellular capped mRNAs are translated by a cap-dependent
“scanning” mechanism, poliovirus and encepholomyocarditis viral
RNAs were ﬁrst shown to use a cap-independent mechanism, which
involves internal entry of ribosome within the 5′ UTR of viral RNA, a
process termed internal ribosome entry site (IRES)-mediated trans-
lation (Pelletier and Sonenberg, 1988; Jang et al., 1988). Since then,ll rights reserved.functional IRES elements have been identiﬁed in many other RNA
viruses including HRV, FMDV, HAV, TMEV, Coxsackie virus, HCV,
classical swine fever virus, murine leukemia virus, simian immuno-
deﬁciency virus, and cricket paralysis virus (reviewed in Hellen and
Sarnow, 2001).
The formation of 48S preinitiation complex containing the initiator
tRNA, mRNA and 40S ribosome by the HCV IRES element requires only
eIF-2 and eIF-3 (Pestova et al., 1998). The 40S ribosome appears to
interact with HCV RNA at multiple sites including stems, loops,
pseudoknots, as well as the initiator AUG. Ribosomal protein S5/S9 as
well as eIF-2B and eIF-2γ have been identiﬁed as co-factors of HCV
IRES-mediated translation (Fukushi et al., 2001a; Kruger et al., 2000).
Although these studies have shed light on the minimum required
canonical factors for HCV IRES-mediated translation, it is apparent
that transacting factors play an important role in modulating IRES
activity (Belsham and Sonenberg, 2000). Cellular proteins such as La
(lupus autoantigen), PTB (polypyrimidine tract binding protein),
PCBP2 (poly rC binding protein 2), C23 (nucleolin), NS1-associated
protein 1 (NSAP1) and unr have been shown to interact with viral
IRES elements and stimulate IRES-mediated translation (Ali and
Siddiqui, 1995, 1997; Ali et al., 2000; Blyn et al., 1997;Meerovich et al.,
1993; Boussadia et al., 2003; Gamarnick and Andino, 1997; Hellen et
al., 1993; Hunt et al., 1999; Izumi et al., 2001). It has been
hypothesized that the transacting proteins may act as “RNA
chaperones” stabilizing IRES secondary and tertiary structures to
allow efﬁcient translation to take place (Belsham and Sonenberg,
2000).
Previous results from our laboratory have shown that an 18-amino
acid-long sequence from the N-terminus of the La autoantigen was
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synthetic peptide (called LAP, for La peptide) corresponding to this
sequence (amino acids 11 to 28) of La was found to efﬁciently inhibit
viral IRES-mediated translation in vitro (Izumi et al., 2004). The LAP
efﬁciently entered Huh-7 cells and preferentially inhibited HCV IRES-
mediated translation programmed by a bicistronic RNA in vivo (Izumi
et al., 2004). The LAP did not bind RNA directly. Preliminary
competition UV crosslink and translation rescue experiments sug-
gested that LAP inhibits IRES-mediated translation by interacting with
proteins rather than RNA. Mutagenesis of LAP demonstrated that
single amino acid changes in a highly conserved sequence within LAP
are sufﬁcient to eliminate the translation-inhibitory activity of LAP.
When one of these mutations (Y23Q) is introduced into full-length La
protein, the mutant protein was found to be severely defective in
interacting with the viral IRES element and consequently unable to
stimulate IRES-mediated translation (Izumi et al., 2004). These results
underscored the importance of the La N-terminal amino acids in RNA
binding and viral RNA translation.
In this study we have investigated the mechanism by which LAP
inhibits HCV IRES-mediated translation. We demonstrate here that
LAP, but not the single amino acid LAPmutant Y23Q, efﬁciently blocks
HCV replication as well as formation of infectious JFH1 virus in cell
culture. Competition UV crosslink analysis show that LAP is able to
block interaction of HCV 5′UTR with a number of IRES transacting
proteins (ITAFs) that include PTB, PCBP2 and La. Gel exclusion
chromatography using puriﬁed ITAFs and FITC-labeled LAP showed
direct interaction of LAP with PTB, PCBP2 and to some extent with La.
Consistent with these data, His-tagged, puriﬁed PTB and PCBP2 were
able to fully rescue HCV 5′ UTR-mediated translation that wasFig. 1. LAP blocks replication of JFH1 HCV in tissue culture. (A) Schematic representation of w
were pretreated with buffer (panels B and C), various concentrations of wt LAP (panels D-G
was then removed, and cells were washed with MEM, followed by infection of cells with JFH
were stained with DAPI, and the other half was scored for NS5A immunoﬂuorescence using
reporter virus was introduced into Huh-7.5.1 cells (by electroporation) that were pretreate
(NSP). The reporter virus lacking polymerase activity (pol-null) is included as negative contr
buffer and the levels of Renilla luciferase were quantiﬁed. The experiment was done in trip
transfection efﬁciency and extract protein concentration) values are presented as a bar g
immediate early promoter was used to determine the percentage of transfected cells by com
the population.inhibited by incubation of Huh-7 translation lysates with LAP. The
puriﬁed La protein could only partially restore LAP-inhibited
translation from the HCV 5′ UTR in vitro. Finally, transient expression
of the PTB/PCBP2 combination was able to reverse LAP-mediated
inhibition of viral replication in culture. These results underscore the
importance of ITAFs in HCV life cycle and demonstrate that these
cellular RNA-binding proteins could be targeted to block HCV
replication.
Results and discussion
LAP blocks replication of JFH1 HCV in tissue culture
Previous results from our laboratory have shown that LAP is able to
efﬁciently enter Huh-7 cells and block HCV IRES-mediated translation
from a bicistronic RNA without signiﬁcantly interfering with cap-
dependent translation (Izumi et al., 2004). It was, therefore, of
considerable interest to determine if LAP could block replication of
HCV in tissue culture. We addressed this question by pretreatment of
Huh-7.5.1 cells with various concentrations of LAP or the Y23Q LAP
mutant for 1–2 h, followed by removal of excess LAP and washing of
cells with PBS. Cells were then infected with the JFH1 virus for 72 h.
Replication of the JFH1 virus was determined by measuring NS5A ex-
pression by immunoﬂuorescence using an antibody to NS5A (Zhong
et al., 2005). As can be seen in Figs. 1B–G, LAP inhibited replication of
JFH1 virus efﬁciently at all concentrations tested. This was in contrast
to the Y23Q LAP mutant, which was unable to block virus replication
signiﬁcantly even at the highest concentration (Figs. 1H–K). Similar
results were obtained when a non-speciﬁc peptide with a scrambledt JFH1 and wt and pol-null luciferase reporter (NRLFC) constructs. (B-K) Huh-7.5.1 cells
), or Y23Q mutant LAP (panels H-K) as described in Materials and methods. Excess LAP
1 virus (moi=1). Infection was stopped at 72-h post-infection, and one half of the cells
anti-NS5A antibody. (L)10 μg of in vitro transcribed genomic RNA of wild-type NRLFC
d with indicated concentrations of wt LAP, or Y23Q mutant or the non-speciﬁc peptide
ol. The transfected cells were lysed at indicated time points using Promega passive lysis
licate and the mean values with standard deviation of Renilla luciferase (corrected for
raph in log10 scale. The lacZ gene (encodes beta-galactosidase protein) under CMV
paring the number of cells expressing the reporter protein to the total number of cells in
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not shown; see Fig. 1L). To quantify the degree of LAP-mediated
inhibition of virus replication, the effect of LAP on virus replication
was determined using a monocistronic Renilla luciferase HCV reporter
virus, NRFLC (Arumugaswami et al., 2008). The mutant reporter RNA
defective in HCV RNA polymerase activity (pol-null) was included as a
negative control for genome replication. The genome replication of
NRFLC was assessed by measuring the Renilla luciferase activity in the
transfected Huh-7.5.1 cells at 6 and 96 h after transfection (Fig. 1L). At
6 h post-transfection the Renilla luciferase activity was mainly due to
translation of the input RNA genome. Wt LAP but not the Y23Q or the
scrambled NSP inhibited translation of the input RNA signiﬁcantly at
early time points (6 h). The signiﬁcant increase in Renilla luciferase
activity at 96 h post-transfection is due to replication of the viral RNA
genome leading to accumulation of signiﬁcantly higher levels of
translatable viral RNA. Thewt LAP signiﬁcantly inhibited replication of
the reporter virus, whereas both the Y23Q LAP and the non-speciﬁc
peptide (scrambledNSP) had no signiﬁcant effect on initial translation
(6 h) or virus replication (96 h). While luciferase production from the
pol-null mutant RNA at 6 h post-transfection was similar to that of the
wt RNA, there was no signiﬁcant increase in luciferase at 96 h due to
lack of RNA replication by the polymerase mutant. These results
suggest LAP is able to block JFH1 virus replication signiﬁcantly in
cultured liver cells and are consistent with our previous report that
LAP could enter Huh-7 cells efﬁciently and block HCV IRES-mediated
translation (Izumi et al., 2004).
LAP interferes with binding of ITAFs to the 5′ UTR of HCV RNA
Previous results from our laboratory suggested that LAP-induced
inhibition of poliovirus 5′UTR-mediated translation occurred through
translation stimulatory proteins rather than through interaction with
viral 5′UTR (Izumi et al., 2004). To examine what cellular proteins
could be involved in LAP-mediated inhibition of HCV IRES-mediated
translation, we examined interaction of cellular proteins (in transla-
tion lysates from Huh-7 cells) with 32P-labeled HCV 5′UTR by UV-
crosslink assay (Das et al., 1996, 1998; Dasgupta et al., 2004) in the
absence and presence of LAP. As can be seen in Fig. 2A, a number of
liver cell-derived proteins having molecular masses between 45 and
100 kDa were found to interact with the HCV 5′UTR (lane 2). Previous
studies from our laboratory have shown that interaction of almost all
of these polypeptides with the HCV 5′UTR could be speciﬁcally
competed with the unlabeled 5′UTR but not a non-speciﬁc RNA of
similar size (Dasgupta et al., 2004). Here we wished to examine if
addition of LAP to the reactionwould block 5′UTR–protein interaction.Fig. 2. LAP blocks HCV 5′UTR–protein interaction of a number of polypeptides from
Huh-7.5 cells. (A) An S10 cell-free translation lysate from Huh-7.5 cells was used for
RNA–protein interaction by UV-crosslinking assay using radiolabeled HCV 5′UTR RNA.
UV-crosslinked protein-nucleotidyl complexes in the absence (lane1) and presence
(lanes 2–6) of S10 containing 40 and 60 μM LAP (lanes 3 and 4) or a non-speciﬁc
peptide, NSP (lanes 5 and 6) were analyzes by SDS-PAGE. (B) Three pooled reactions as
in lane 2 above were used for individual immunoprecipitation of protein-nucleotidyl
complexes with anti-La (lane 1), anti-PTB (lane 2), and anti-PCBP2 (lane 3) antibodies.Indeed, LAP blocked interaction of these polypeptides with the 5′UTR
when used at ﬁnal concentrations of 40 and 60 μM (lanes 3 and 4). A
non-speciﬁc scrambled peptide, however, was unable to block RNA–
protein interaction signiﬁcantly (lanes 5 and 6). These results suggest
that LAP interferes with cellular protein binding to the HCV 5′UTR.
In order to gain insight into the nature of proteins whose
interactions with the HCV 5′UTR are blocked by LAP, we used
immunoprecipitation of the UV-crosslinked complexes using anti-
bodies to known IRES-transacting factors (ITAFs). As can be seen in
Fig. 2B, at least three UV-crosslinked protein-nucleotidyl complexes
having approximate molecular masses of 57, 52 and 45 kDa could be
immunoprecipitated with antibodies to polypyrimidine tract binding
protein (PTB), Lupus autoantigen (La), and poly(rC) binding protein 2
(PCBP2), respectively. The identity of the two other major protein-
nucleotidyl complexes, p100 and p65 is not known at present.
However, we believe that the 65 kDa protein, which is cross-linked to
HCV 5′UTR could be the NS1-associated protein 1, which binds to HCV
RNA core-encoding sequences downstream of the HCV IRES and
stimulates HCV IRES-mediated translation (Kim et al., 2004).
A100 kDa protein, which interacts with and stimulates translation
programmed by the rhinovirus 5′UTR, was identiﬁed to be nucleolin
in a previous study (Izumi et al., 2001). It remains to be seen whether
the 100-kDa protein we detected here (Fig. 2) is actually nucleolin.
These results suggest that LAP interferes with binding of ITAFs to the
HCV IRES element.
Interaction of LAP with ITAFS in vitro
To determine if LAP directly interacts with PTB, PCBP2 and La, we
utilized gel exclusion chromatography capable of separating free LAP
from ITAF-bound LAP. For this purpose each recombinant ITAF was
expressed in bacteria and the His-tagged proteins were puriﬁed by
afﬁnity chromatography. Fig. 3B shows two peak fractions from
afﬁnity column chromatography containing His-La, His-PTB, and His-
PCBP2 proteins. In addition to the full-length wt proteins, we also
expressed and puriﬁed the N-terminal (amino acids 1–327) and C-
terminal (amino acids 328–557) fragments of PTB as well as two La
mutants: ΔN28La (N-terminal 28 amino acids deleted) and Y23QLa.
We also puriﬁed the LAP peptide, which runs on SDS-PAGE as an 8–
9 kDa peptide (actual molecular weight 2 kDa). Identity of each
recombinant protein was veriﬁed by immunoblot analysis using anti-
His antibody (data not shown).
Interaction of each puriﬁed protein with FITC-labeled LAP (Izumi
et al., 2004) was examined by gel ﬁltration of the reaction mixture
following incubation of the protein with FITC-LAP. Under the assay
condition, the majority of free FITC-LAP eluted between fractions 20
and 33 (Fig. 4B). When incubated with highly puriﬁed PTB prior to gel
ﬁltration, a signiﬁcant fraction of the FITC-LAP eluted between
fractions 5 and 9 (Fig. 4A). Immunoblot analysis of these fractions
using anti-PTB showed co-elution of the PTB with the FITC-LAP
(Fig. 4C), suggesting formation of FITC-LAP: PTB complex. Similar
results were observed when highly puriﬁed PCBP2 was incubated
with FITC-LAP followed by gel ﬁltration; the majority of the PCBP2
eluted between fractions 6 and 10, which coincided with the protein
bound FITC-LAP elution (Figs. 4A and D). Unlike PTB and PCBP2,
signiﬁcantly smaller quantities of FITC-LAP was found to co-elute
from the column with the wt La protein between fractions 6 and 9
(Figs. 4A and E). In contrast to the ITAFs, ovalbumin, which eluted
from the gel ﬁltration column between fractions 7 and 10, did not bind
any FITC-LAP (Figs. 4A and F). These results suggest that LAP interacts
with PTB, PCBP2 and to some extent with La. It is interesting to note
that another 24 amino acids long synthetic peptide, La R2C, derived
from La RRM (amino acids 112–184) was recently reported (Mondal
et al., 2008). This peptide also inhibited HCV IRES-mediated
translation, but unlike LAP, it retained RNA binding ability and
competed with La protein binding to the HCV IRES.
Fig. 3. Expression and puriﬁcation of His-tagged recombinant ITAFs. (A) The schematics of domain structures of wt La, Y23Q La, ΔN28 La, wt PTB, PTB N3, PTB C7 and PCBP2 are
shown. The amino acid sequences of wt LAP and y23Q La are shown at the top. (B) Various wt ormutant ITAFs taggedwith 6X His as indicated were expressed in bacteria and puriﬁed
by Ni-afﬁnity column chromatography. The fractions containing recombinant proteins eluting from the ﬁnal Ni-column were examined by SDS-PAGE followed by Coomassie blue
staining. The two peak fractions from each preparation used in the following assays are shown. Western blot analysis of FITC-LAP at two concentrations using anti-La antibody
is shown.
85V. Fontanes et al. / Virology 394 (2009) 82–90PTB is a modular protein, with four noncanonical RNA binding
domains (RNA RecognitionMotifs, RRM) that are tethered together by
conserved linker domains (Fig. 3). The NMR structures of all four
RRMs have been resolved (Conte et al., 2000; Simpson et al., 2004). It
is not known if the RRMs function independently or synergistically,
nor is it understood how they are positioned with respect to eachFig. 4. LAP-ITAF interaction. Various puriﬁed His-ITAFs were incubated individually with pur
and FITC-LAP in a reaction volume of 100 μl were 12 μM and 28 μM, respectively. The speci
passed through a Sepahcryl S-200 gel ﬁltration column. Elution proﬁles of FITC-LAP in the abs
(La: FITC-LAP), and ovalbumin (Ovalbumin: FITC-LAP) (panel A) are shown. Fractions 3–10
anti-His antibody. Panel F shows elution proﬁle of ovalbumin as determined by silver stainother in the free protein or on an RNA substrate. During poliovirus
infection, the viral protease 3CDpro cleaves PTB within the linker
between RRM2 and RRM3. This separation of PTB into two fragments
suggests that each could be used as independent units by the virus,
and perhaps also by the cell. To gain a better understanding of how
LAP interacts with PTB that leads to its RNA binding inability, weiﬁed FITC-LAP as described in Materials and methods. The ﬁnal concentrations of ITAFs
ﬁc activity of FITC-LAP was 10 ﬂuorescent units per pmol. The reaction mixtures were
ence (panel B) and in the presence of PTB (PTB: FITC-LAP), PCBP2 (PCBP2: FITC-LAP), La
from gel ﬁltration columns with individual ITAF were examined by Western blot using
ing of the gel.
Fig. 6. PTB and PCBP2 restore LAP-induced inhibition of HCV IRES-mediated translation
in vitro. (A) In vitro translation of HCV 5′UTR-CAT mRNA in translation lysates from
Huh-7.5 cells in the absence (lane 1) and presence (lanes 2–5) of 60 μM LAP at 15, 30
and 60 μg of additional lysates (lanes 3, 4 and 5). (B) Translation from HCV 5′UTR-CAT
RNA in the absence (lane 1) and presence (lane 2–4) of 60 μM LAP with 500 nM and
1 μM added puriﬁed La protein (lanes 3 and 4). (C) Poliovirus IRES (5′UTR-CAT)-
mediated translation in reticulocyte lysates was performed in the absence (lane 1) and
presence of 250 nM, 500 nM, and 1 μM puriﬁed La (lanes 2, 3 and 4) and 1 μM puriﬁed
Y23Q La (lane 5). (D) In vitro translation from HCV 5′UTR-CAT in the absence (lane 1)
and presence of 60 μM LAP (lanes 2–4) with exogenously added 275 and 550 nM
puriﬁed PCBP2 (lanes 3 and 4). (E) Translation from HCV 5′UTR-CAT in the absence
(lane 1) and presence of 275 nM (lane 2) and 550 nM (lane 3) PCBP2. (F) In vitro
translation from HCV 5′UTR-CAT in the absence (lane 1) and presence of 60 μM LAP
(lanes 2–4) with exogenously added 250 and 500 nM puriﬁed PTB (lanes 3 and 4). (G)
Translation from HCV 5′UTR-CAT in the absence (lane 1) and presence of 250 and
500 nM PTB (lanes 3 and 4). (H) In vitro translation from HCV 5′UTR-CAT in the absence
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terminal sequences having RRMs 1 and 2 (called N3 PTB), and the
other having the C-terminal sequences containing RRMs 3 and 4
(called C7 PTB) (Fig. 3).We then examined interaction of each of these
PTB fragments with FITC-LAP by analyzing the protein-FITC-LAP
complexes following gel ﬁltration. As can be seen in Fig. 5, although
both fragments were defective in interacting with FITC-LAP compared
to the wt PTB, small but signiﬁcant binding of both N3 and C7 PTB was
detected. However, the areas under the N3PTB: FITC-LAP and C7PTB:
FITC-LAP complexeswere signiﬁcantly reduced compared to that with
the wt PTB. The protein proﬁles of these fractions as determined by
immunoblotting using anti-His showed that the high molecular
weight fractions containing small but signiﬁcant amount of FITC-
LAP indeed contained the truncated proteins (Figs. 5B–D). These
results suggest that the entire PTB molecule is required for efﬁcient
interaction with LAP.
PTB and PCBP2 but not La completely rescue LAP-mediated translation
inhibition from the HCV IRES
We addressed the functional signiﬁcance of LAP-ITAF interactions
by examining whether the puriﬁed ITAFs could rescue LAP-mediated
inhibition of translation programmed by the HCV 5′UTR. Cell-free
translation lysates prepared from Huh-7 cells were used for in vitro
translation of HCV 5′UTR-CAT mRNA in the absence or presence of
various His-tagged, puriﬁed ITAFs. As can be seen in Fig. 6A,
exogenous addition of Huh-7 cell-free extracts to LAP-inhibited
translation reactions completely restored translation from the HCV
5′UTR. Puriﬁed His-La, on the other hand, was only partially active in
rescuing LAP-mediate translation inhibition (Fig. 6B). Addition of
even higher concentrations of His-La inhibited translation non-
speciﬁcally (data not shown). The puriﬁed His-La protein, however,
was functional since it could restore translation of poliovirus mRNA in
rabbit reticulocyte lysates, which lacks the La protein (Fig. 6C). These
results suggest that a functionally active La is unable to fully restore
LAP-induced inhibition of HCV IRES-mediated translation. In contrast
to the La protein, both PCBP2 and PTB could fully rescue LAP inhibition
of HCV 5′UTR-mediated translation (Figs. 6D and F). Like His-La,
addition of higher concentrations of His-PTB and His-PCBP2 also
inhibited translation (data not shown). Addition of PCBP2 or PTB to
the translation lysates in the absence of LAP only marginally
stimulated translation from the HCV 5′UTR (Figs. 6E and G),
suggesting that the cell-free lysates were not signiﬁcantly limiting
in these proteins. Ovalbumin, which did not form a detectable
complex with FITC-LAP (Fig. 4), was almost totally ineffective inFig. 5. Interaction of wt PTB, N3PTB and C7 PTB with FITC-LAP. The elution proﬁles of
PTB, N3 PTB, and C7 PTB in complex with FITC-LAP are shown in panel A. Panels B–D
show elution of wt, N3, and C7 PTB, respectively as determined by immunoblot analysis.
(lane 1) and presence of 60 μM LAP (lanes 2–4) with exogenously added 275 and
550 nM puriﬁed ovalbumin (lanes 3 and 4). (I) In vitro cap-dependent translation of
capped-CAT RNA in the absence (lanes 1, 3, 5, 7) and presence (lanes 2, 4, 6, 8) of 60 μM
LAP with 500 nM PTB (lanes 3 and 4), 550 nM PCBP2 (lanes 5 and 6), and 500 nM La
(lanes 7 and 8).restoring LAP-mediated translation inhibition (Fig. 6H). LAP had no
signiﬁcant effect on cap-dependent translation from a capped-CAT
RNA. In fact, marginal stimulation of cap-dependent translation was
observed in the presence of LAP (Fig. 6I, lanes 1 and 2). Under the
condition of our assay, addition of La, PTB, or PCBP2 individually to the
reaction did not signiﬁcantly affect cap-dependent translation in the
presence or absence of LAP (Fig. 6I, lanes 3–8). Thus, a direct
correlation between translation rescue by the puriﬁed ITAFs (Fig. 6)
and their ability to form complex with LAP (Fig. 4) was observed.
While PTB and PCBP2 were found to completely rescue LAP-induced
inhibition of in vitro translation programmed by the HCV 5′UTR, the
puriﬁed La protein only partially rescued HCV IRES-mediated
translation in the presence of LAP, suggesting PTB and PCBP2, but
not La, were mainly being sequestered by LAP leading to inhibition of
HCV IRES-mediated translation.
Fig. 8. Transient expression of PTB and PCBP2 can partially restore LAP-mediated
inhibition of JFH1 HCV replication in cell culture. Ten microgram of in vitro transcribed
genomic RNA of wild-type NRLFC reporter virus was co-transfected into control buffer-
or LAP-treated Huh-7.5.1 cells with empty mammalian expression vector (pCVector),
pCPTB, or pCPCBP2, or both pCPTB and pCPCBP2 as indicated. The mutant reporter virus
lacking polymerase activity (pol-null) was included as control. The transfected cells
were lysed at 96 h post-transfection using Promega passive lysis buffer and the levels of
Renilla luciferase were quantiﬁed. Three experiments were done in triplicate and the
mean values with standard deviation of Renilla luciferase values (RLV) are presented as
a bar graph in log10 scale. The data were also corrected with respect to transfection
efﬁciency and extract protein concentration.
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LAP-induced translation inhibition in vitro
We were surprised by the fact that LAP did not interact efﬁciently
with the wt La protein, while it interacted efﬁciently with two other
ITAFs (PTB and PCBP2) (Fig. 4A). A curious ﬁnding was that, while the
wt La protein bound very little FITC-LAP, both the Y23Q and ΔN28La
mutants were as active as PTB (or PCBP2) in sequestering FITC-LAP in
the gel ﬁltration assay (Fig. 7). The gel ﬁltration proﬁle of these two La
mutants suggested that the single amino acid change in the La protein
or the deletion of the N-terminal 28 amino acids altered the structure
of these proteins in such a way that they were eluted from the gel
ﬁltration column ahead of the wt La protein (Fig. 7B). The structural
changes induced by these mutations most probably were responsible
for renewed LAP binding ability of the mutant La proteins.
To determine if the renewed ability of the La mutants to bind LAP
efﬁciently could also lead to their ability to restore HCV IRES-
mediated translation in LAP-inhibited (translation) extracts, various
amounts of the puriﬁed, recombinant, His-tagged Y23Q and ΔN28 La
mutant polypeptides were added to LAP-inhibited translation
extracts. As can be seen in Fig. 7C, LAP-induced inhibition of HCV
IRES-mediated translation could be almost fully reversed by both La
mutants, but not by the wt La protein. Thus, as found with the wt PTB
and PCBP2 proteins, the ability to sequester LAP by the La mutants
resulted in rescue of translation in LAP-inhibited translation extracts.
These results suggest that deletion of the La N-terminal 28 amino
acids or substitution of the La Y23with Q leads to signiﬁcant change in
protein structure resulting in efﬁcient La-LAP interaction (Fig. 7B)
leading to reversal of translation.
PTB and PCBP2 rescues LAP-mediated inhibition of HCV replication
in cell culture
To determine whether ITAFs are able to rescue LAP-mediated
inhibition of JFH1 replication in cultured Huh-7.5.1 cells, the effects of
PTB and PCBP2 expression on NRFLC virus replication were examined
in control buffer- and LAP-treated cells. When expressed individually,
slight recovery of virus replication in LAP-treated cells, asmeasured by
RLuc production,was observed for bothpCPTB andpCPCBP2 compared
to the empty vector (pCVector). Inclusion of both pCPTB and pCPCBP2
during transfection, however, resulted in signiﬁcant recovery of virus
replication in LAP-treated cells compared to that in buffer-treated (no
LAP) cells. The slight increase in virus replication seen in control
buffer-treated cells transfected with both pPTB and pPCBP2 compared
to the empty vector-treated cells was possibly due to presence of
limiting amounts of these ITAFs in Huh-7.5.1 cells. In contrast to wt
NRFLC, the expression of PTB and PCBP2 did not have any signiﬁcantFig. 7. The La N-terminal 28 amino acid deletion or Y23Q substitution stimulate interac
Y23QLa: FITC-LAP are shown in panel A. Panel B shows immunoblot analyses of eluted w
inhibited HCV 5′UTR-mediated in vitro translation by wt La, ΔN28La, and Y23Q La prote
separate experiments are shown.effect onNRLFCpol-nullmutant replication indicating the ability of the
ITAFs to reverse LAP-mediated inhibition required active replication of
the NRFLC virus. Our cell culture data suggest that PTB and PCBP2 act
synergistically in rescuing LAP-mediated inhibition of HCV replication
in tissue culture cells (Fig. 8). This is in contrast to our in vitro data
where LAP-induced inhibition of HCV IRES-mediated translation could
be almost completely rescued by individual ITAFs (Fig. 6). We do not
know the precise reason for this discrepancy. One possibility could be
that while the in vitro assay measures only translation, the cell based
assay measures both translation and multiple cycles of virus
replication. How these processes are precisely inﬂuenced by LAP as
well as ITAFs under these two different assay conditions is not known
and could contribute to the observed difference.
The lifecycle of RNA viruses could be potentially interfered with at
various stages such as virus-receptor interaction, viral entry, viral
protein synthesis, polyprotein processing, RNA synthesis, viral
assembly / morphogenesis and release. We have described here the
utility of a small, cell-permeable and stable peptide inhibitor, whichtion with FITC-LAP. The elution proﬁles of Wt La: FITC-LAP, ΔN28La: FITC-LAP, and
t and mutant La proteins in relevant column fractions. Panel C shows rescue of LAP-
ins. All reactions in this experiment contain 60 μM LAP. Averaged results from two
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utilize cap-independent translation to synthesize viral proteins. We
have shown that the eighteen amino acid long peptide efﬁciently
blocks replication of hepatitis C virus (HCV) in tissue culture. The LAP
appears to block viral IRES-mediated protein synthesis by sequester-
ingmainly two IRES-transacting factors: polypyrimidine track binding
protein (PTB) and poly(rC) binding protein 2 (PCBP2). These results
are consistent with previously described roles of PTB and PCBP2 in
HCV RNA replication (Aizaki et al., 2006; Chang and Luo, 2006;
Fukushi et al., 2001b; Randall et al., 2007; Zhang et al., 2004).
Although our previous data (Izumi et al., 2004) and the results
presented here suggest that LAP interferes with HCV IRES-mediated
translation possibly through PTB and PCBP2, we cannot rule out the
possibility that LAP could also interfere with HCV RNA synthesis. In
fact, the roles of both proteins (PTB and PCBP2) in HCV RNA synthesis
have been suggested by a number of reports (Aizaki et al., 2006;
Chang and Luo, 2006; Domitrovich et al., 2005; Fukushi et al., 2001b).
Thus, sequestration of PTB and PCBP2 by LAP could potentially block
viral RNA synthesis in addition to viral translation.
Materials and methods
Cells
The Huh-7.5 and Huh-7.5.1 cell lines (kindly provided by Dr.
Francis Chisari, The Scripps Research Institute, La Jolla, and Dr. Charles
Rice, Rockefeller University, NY) were cultured in complete DMEM
containing 10% fetal bovine serum, 10 mM non-essential amino acids
(Invitrogen), 10 mM HEPES, penicillin (100 units/ml), streptomycin
(100 mg/ml), and 2 mM L-glutamine at 37 °C with 5% CO2.
Peptides and FITC labeling of peptides
LAP peptides were synthesized and puriﬁed to N95% homogeneity
by Bio-Synthesis, Inc. For ﬂuorescein isothiocyanate (FITC) labeling,
the peptides were dissolved in phosphate-buffered saline (PBS; pH
8.0). Peptides were labeled using FluoReporter FITC labeling Kit (F-
6434, Molecular Probes), according to manufacturer's speciﬁcations
with a slight variation. After labeling, peptides were puriﬁed using
Quick Spin RNA Puriﬁcation Column (Roche) (24) Aliquots were
stored protected from light at −80 °C. For cell treatment, peptides
were dissolved in 100mMTris pH 8.0 to 5mM as previously described
(Izumi et al., 2004).
LAP treatment of cells
Before transfection or infection, the cells were pretreated with
various concentrations of LAP, Y23Q LAP or a non-speciﬁc scrambled
peptide (NSP) for 2 h. Cells were then washed three times with PBS to
remove excess peptide, and either infected with JFH1 or transfected
with appropriate plasmids. HCV or transfected with appropriate
plasmids At appropriate times post transfection or infection, the cells
were examined by confocal microscopy following immunoﬂuores-
cence using anti-NS5A.
Virus and plasmid constructs
The plasmid containing the complete genome of a HCVGT2a strain
JFH-1 was kindly provided by Dr. Takaji Wakita, National Institute of
Infectious Diseases, Japan (Wakita et al., 2005). An intra-genotype
chimeric virus, pJ6/JFH-C, comprising 5′NTR, structural regions and
part of non-structural regions (p7 and partial NS2) of the J6CF strain
(NCBI accession no. AF177036) and non-structural regions of JFH-1
strain was generated (Arumugaswami et al., 2008). The J6CF genomic
region, nt 1 to 2878, was synthesized by PCR based assembly of
oligonucleotides (Invitrogen). The T7 promoter sequence (5′-TAA-TACGACTCACTATAG-3′) and nt 2879 to 2967 of the JFH-1 isolate was
engineered at the 5′ and 3′ ends of the J6CF 1–2878 fragment,
respectively. The ﬁnal assembled PCR product (T7-J6CF/JFH) was
cloned into pZero-blunt vector (Invitrogen) and sequence veriﬁed.
The EcoRI–NotI fragment (2.9 kb) of the pJFH-1 was swappedwith the
assembled T7-J6CF/JFH fragment to obtain pJ6/JFH-C. A monocis-
tronic chimeric reporter virus, pNRLFC based on pJ6/JFH-C parental
virus was constructed. A plasmid containing a reporter cassette, T7-5′
NTR (388 nucleotides)-Renilla luciferase gene-F2A seqeuce-Core-E1,
was constructed. The F2A sequence introduced was 5′-GTGAAACA-
GACTTTGAATTTTGACCTTCTCAAGTTGGCCGGAGACGTCGAGTCCAAC-
CCTGGGCCC -3′. The EcoRI–BsiSWI fragment containing the reporter
cassette was subcloned into pJ6/JFH-C to construct pNRLFC. To
construct the envelope-null mutant virus, an in-frame deletion of nt
1040–2215 was engineered in the pJ6/JFH-C genome. This deletion
removed most of the E1 and E2 coding regions. An identical E1 and E2
deletion mutant reporter virus pNRLFC was also constructed. An RNA
polymerase-null virus with pJ6/JFH-C or pNRLFC background was
constructed by mutating the catalytic residues GDD to AAG amino
acid residues. The NotI restriction enzyme site present in JFH1
genome at nt 2955 was abolished by PCR-mediated introduction of
silent point mutations (CGGC→TGGT). These point mutations did not
affect virus infectivity (data not shown).
Virus production and infection
pJFH-1 plasmid (Wakita et al., 2005) was linearized by XbaI
restriction digestion, and treated with MungBean nuclease (New
England BioLabs). 1 μg linearized DNA was in vitro transcribed using
T7 RiboMAX™Large Scale RNA Production System (Promega). 10 μg
transcribed RNA was electroporated into 106 Huh 7.5.1 cells and virus
production monitored. Highest titer virus was used for following
infection experiments. Huh 7.5.1 cells were seeded in 48 well plates;
when cell conﬂuency reached ∼30%, they were treated overnight with
LAP peptide in a total volume of 300 μL. Cells were infected at an moi
of 0.1 to 1 h and adsorption allowed for 4 h, at which time cells were
washed and fresh media was added with or without peptides. After
72 h, samples were collected and assayed for viral RNA and viral
protein after cell lysis. Quantiﬁcation of intracellular virus production
and secreted virus were determined as previously described (Aru-
mugaswami et al., 2008). Brieﬂy, cell-free culture supernatants or
freeze-thawed lysates were serially diluted and used to infect 3×103
naïve Huh 7.5.1 cells in a 96 well plate. After 72 h cells were washed
with cold PBS, ﬁxed with methanol for 30 min at room temperature
and stained for viral protein NS5A for further analysis of foci
formation using immunoﬂuorescence.
Determination of virus titer
The virus titer was measured as previously described (Arumu-
gaswami et al., 2008) by calculating the foci forming unit (ffu) of
infectious viral particles per ml of cell-free culture supernatant
(Zhong et al., 2005). The infected culture supernatant was 10-fold
serially diluted in complete DMEM and inoculated in triplicate onto
naïve Huh-7.5.1 cells (3×103 cells/well) in 96-well plates. At 72 or
96 hpi, the cells were ﬁxed and immunostained for HCV core antigen.
The number of core antigen positive foci were counted at the highest
dilution and average foci forming units per ml was calculated.
Renilla luciferase reporter assay for viral genome replication
and infectivity
For viral genome replication assay, the HCV RNA transfected cells
were plated in triplicates in 48-well plates. The cells were lysed with
passive lysis buffer (Promega) at 6 and 96 hpt. The culture plates were
gently rocked at room temperature for 15 min, then stored at−80 °C.
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tant obtained from HCV RNA transfected cells at 48 and 96 hpt was
inoculated in triplicate onto naïve Huh-7.5.1 cells in 48-well plates. At
48 hpi the cells were lysed and stored at −80 °C. 10 μl of lysate was
used for measuring the Renilla luciferase activity using a Renilla
Luciferase Assay System kit (Promega) as previously described
(Arumugaswami et al., 2008).
Plasmid construction and protein expression
His-tagged proteins were cloned into the pET-100/D TOPO®
Directional Expression System according to manufacturer's speciﬁca-
tions (Invitrogen). Primers (IDT DNA, Coralville, IA) used for cloning
of the La proteins are as follows: La/Y23Q fwd ( 5′c acc atg gct gaa aat
ggt gat aat gaa aag atg g 3′), LaΔ28 fwd (5′ c acc aat ttg cca cgg gac aag
ttt cta aag 3′) and La/Y23Q/Δ28 rev (5′ cta ctg gtc tcc agc acc att ttc tg
3′). Primers for PTB and truncated proteins: PTB/PTBΔC fwd (5′ c acc
atg gac ggc att gtc cc 3′), PTBΔN fwd (5′ c acc aac gtc cac ggc gcc c 3′),
PTB rev (5′ cta gat ggt gga ctt gga gaa gga gac c 3′) and PTBΔC rev (5′
cta aac gga aag gcc tgc agc ttg agg 3′). Primers for PCBP2 fwd (5′ c acc
atg gac acc ggt gtg att gaa gg 3′) and PCP2 rev (5′ cta gct gct ccc cat gcc
acc cg 3′). Proteins were overexpressed in E. coli BL21 star (DE 3) cells
(Invitrogen). Brieﬂy, overnight bacterial cultures were inoculated into
1 L fresh LB media; when the OD reached 0.6–0.8, protein expression
was induced by addition of 1 μM IPTG for 4 h at 37 °C. Cells were
collected by centrifugation and stored at −80 °C for later protein
puriﬁcation. For expression in tissue culture cells, the cDNAs were
subcloned into pCDNA3.1.
Protein puriﬁcation
Bacterial pellets were lysed in 30 mL Resuspension Buffer (25 mM
Tris, 400 mM NaCl, 10% glycerol, pH=7.8, protease inhibitor cocktail)
with 75 μg lysozyme and incubated for 1 h at room temperature under
constant shaking. NP-40 (1%) was added and incubated at 4° for 2 h
under constant shaking. The samples were then sonicated and
centrifuged at 12 K rpm for 30 min. DNA was precipitated with 3%
streptomycin sulfate and lysate cleared by centrifugation at 12 K rpm
for 30 min. Pre-equilibrated beads (ProBond, Invitrogen) were added
to lysate and incubated for 2 h. Beads were packed into columns
(Poly-Prep Chromatography Columns, Bio-rad) and washed with
40 mL Wash Buffer (25 mM Tris, 15 mM Imidazole, 300 mM NaCl,
0.05% NP-40, 10% glycerol, pH=6.8). Proteins were eluted using an
imidazole gradient: 50–300 mM imidazole, and dialyzed overnight
against Binding Buffer (25 mM Tris, 80 mM KCl, 1.5 mM Mg(OAc)2,
2.5 mMDTT, 5% glycerol, 0.025 NP-40, pH, 7.5). Puriﬁed proteins were
concentrated, aliquoted and stored at −80 °C for further binding
assays.
Preparation of cell-free translation extracts and in vitro translation
Trypsinized Huh-7.5 cells as described previously by Svitkin et al.
(2005) were collected by centrifugation, washed (three times) and
the cell pellet was resuspended in 2 volumes of a buffer containing
25 mM HEPES-KOH, pH 7.3, 50 mM KCl, 1.5 mM MgCl2, 1 mM
dithiothreitol (DTT). The cells were allowed to swell on ice for 20 min
and then were broken with 20 to 30 strokes of a tight-ﬁtting Dounce
homogenizer. One-ninth volume of the buffer containing 25 mM
HEPES-KOH, pH 7.3, 1 M K(OAc), 30 mM MgCl2, 30 mM DTT) was
added to the homogenate, and the homogenate was centrifuged at
18,000×g for 20 min at 4 °C. The supernatant was frozen in small
aliquots and stored at –70 °C. Translation reaction mixtures (20 μl)
contained 9 μl of S10, 2 μl of a master mix (Svitkin et al., 2005), 2 μl of a
salt solution (1 M KCl, 5 mM MgCl2, and 2.5 mM spermidine, unless
otherwise speciﬁed), 1 μl of [35S]methionine (10 mCi/ml; 1200 Ci/
mmol), and 0.4 μg HCV RNA (unless otherwise speciﬁed). Translationin RRL was performed as recommended by the manufacturer
(Promega), with the exception that KCl and MgCl2 were included in
the reaction cocktail (at 100 mM and 0.75 mM ﬁnal concentrations,
respectively). The reactions were carried out at 32 °C for 3 h.
Protein binding assay and gel ﬁltration
For binding assay, 75 μg puriﬁed protein was incubated with 10 μL
labeled peptide in Binding Buffer; then, incubated at 37 °C for 2 h.
Sample was loaded into a previously equilibrated Gel Filtration
Column (Sephacryl S-200 HR, Amersham Biosciences). Fractions were
eluted in 200 μl fractions and samples analyzed for ﬂuorescence
(VersaFluor, Bio-rad) and western blotting.
UV crosslinking assay
Recombinant wt La, PTB, PCBP2 and their mutants were incubated
with radiolabeled HCV 5′-UTR (∼106 cpm), for 10 min at 30 °C. After
binding, the reactions were processed as described previously (24).
Western blotting
Protein samples were ran on Tris-HCl ReadyCast gels (Bio-rad) and
transferred to nitrocellulose membranes. Membranes were incubated
with primary antibodies in 4% non-fat milk (FITC pAb-Abcam, Penta-
His mAb-Qiagen, core pAB, α-tubulin mAb-T5168 Sigma-Aldrich),
washed and incubated with secondary antibodies. Proteins were
detected using the ImmunStar HRP Detection Kit (Bio-rad).
Immunoﬂuorescence
After methanol ﬁxation, plates were stored at−20 °C until further
processing. Cells were washed with PBS and blocked overnight at 4 °C
with blocking buffer (3% FBS, 3%BSA, 0.1% Triton X-100 in PBS). Then,
cells were incubated with our NS5A polyclonal antibody (1:300) for
1.5 h at room temperature, followed by secondary goat anti-rabbit
(#111-116-144, Jackson Immunologicals). After washing with sec-
ondary antibody, cell nuclei were stained with DAPI (10 μg/mL) for
10 min, and samples stored in PBS for examination under ﬂuorescent
microscope.
RNA puriﬁcation and RT-PCR
RNA from infected cells was extracted with TRIzol Reagent
(Invitrogen) according to manufacturer's speciﬁcations. Sample was
dissolved in nuclease-free water and further used for RT-PCR using
SuperScript™III One-Step RT-PCR (Invitrogen). Brieﬂy, 30 ng total
RNA was used for 25 μL reactions containing, 10 pmol each NS2
primer, and 1.5 pmol each GAPDH primer. RT: 55 °C for 40 min; PCR:
28 cycles of 94 °C—30 s, 57 °C—15 s, 68 °C 1 min. Primers: NS2 fwd (5′
gac gca cct gtg cac gga cag 3′); NS2 rev (5′gga gct tcc acc cct tgg agg tg
3′); GAPDH fwd(5′ gag tcc act ggc gtc ttc acc ac 3′) and GAPDH rev (5′
cag gtc agg tcc acc act gac ac 3′).
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